X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
Copellor (ixekizumab) is a human IgG mAb that selectively binds to IL-17A and prevents IL-17A binding to IL-17 receptor. Thus, this attenuates an inflammatory response mediated by interleukin 17A. It is indicated treat moderate-to-severe plaque psoriasis.
Lead Product(s): Ixekizumab
Therapeutic Area: Dermatology Product Name: Copellor
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
The new Taltz (Ixekizumab) formulation significantly reduced injection site pain experienced by some people immediately following injection as shown by an 86% decrease in a visual analog scale (VAS) of pain versus the original formulation.
Lead Product(s): Ixekizumab
Therapeutic Area: Dermatology Product Name: Taltz
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
Through clinical trial meta-analysis and real-world evidence, Eli Lilly Taltz® (ixekizumab) demonstrated greater success in key measured treatment outcomes compared to other biologics in adults with moderate to severe plaque psoriasis.
Lead Product(s): Ixekizumab
Therapeutic Area: Dermatology Product Name: Taltz
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2021
Details:
89 per cent of patients treated with Taltz achieved PASI 75 compared to 25 per cent of patients treated with placebo. 81 per cent of patients treated with Taltz achieved sPGA 0,1 compared to 11 per cent of patients treated with placebo.
Lead Product(s): Ixekizumab
Therapeutic Area: Dermatology Product Name: Taltz
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2021
Details:
The U.S FDA has approved a supplemental Biologics License Application for Taltz® (ixekizumab) injection, 80 mg/mL for the treatment of pediatric patients (ages 6 to under 18) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Lead Product(s): Ixekizumab
Therapeutic Area: Dermatology Product Name: Taltz
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2021
Details:
Taltz demonstrated sustained efficacy in adult psoriasis patients with baseline scalp, nail and palmoplantar (skin on the palms of the hands and soles of the feet) involvement with the following results at five years.
Lead Product(s): Ixekizumab
Therapeutic Area: Dermatology Product Name: Taltz
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Highlights of the data being presented at this year's AAD meeting include additional results from BREEZE-AD1 and BREEZE-AD2, Lilly's Phase 3 trials that are part of the baricitinib development program to support global submissions for baricitinib as a treatment for AD.
Lead Product(s): Ixekizumab
Therapeutic Area: Dermatology Product Name: Taltz
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
This approval is based on the results from the Phase 3 COAST-X trial, which evaluated improvement in signs and symptoms of nr-axSpA as measured by the proportion of patients who achieved ASAS40 response criteria compared to placebo.
Lead Product(s): Ixekizumab
Therapeutic Area: Immunology Product Name: Taltz
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
